Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin

被引:33
作者
Fukamachi, Toshihiko [1 ]
Chiba, Yoshie [1 ]
Wang, Xin [1 ]
Saito, Hiromi [1 ]
Tagawa, Masatoshi [2 ]
Kobayashi, Hiroshi [1 ]
机构
[1] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan
[2] Chiba Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Chiba 2608717, Japan
关键词
Anti-cancer reagents; Acidic pH; Lovastatin; Cantharidin; Mesothelioma; Pancreatic carcinoma; MALIGNANT MESOTHELIOMA CELLS; KAPPA-B-BETA; PANCREATIC-CANCER; ACIDIC ENVIRONMENTS; INDUCED APOPTOSIS; CORONARY EVENTS; NITRIC-OXIDE; IN-VITRO; RESISTANCE; INHIBITION;
D O I
10.1016/j.canlet.2010.05.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In tumor cell masses, the extracellular pH decreases below 6.5. The effect of external acidic pH on the efficacy of 24 chemical compounds including molecular-targeted inhibitors and anti-tumor reagents was investigated in human cancer cells. Lovastatin showed no cytotoxicity in mesothelioma or pancreatic carcinoma cells at concentrations up to 10 mu M and pH around 7.4, but 10 mu M lovastatin decreased the survival of these cells below 40% at acidic pH. Lovastatin inhibits HMG-CoA reductase, resulting in a decrease in the levels of cholesterol and prenylated proteins. An inhibitor of the former pathway showed pH-independent cytotoxic activity, whereas an inhibitor of the latter pathway had stronger activity at acidic pH. The inhibitory efficacy of cantharidin also increased at acidic pH. On the other hands, no pH dependency or slightly impaired efficacy at low pH conditions was observed in other 20 reagents, and especially, the activity of aphidicolin was suppressed under acidic conditions. These results suggested that screening under acidic conditions would be useful for developing new chemotherapeutic reagents. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:182 / 189
页数:8
相关论文
共 41 条
[1]   Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells [J].
Catalano, A ;
Rodilossi, S ;
Rippo, MR ;
Caprari, P ;
Procopio, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (45) :46706-46714
[2]   Statins and cancer prevention [J].
Demierre, MF ;
Higgins, PDR ;
Gruber, SB ;
Hawk, E ;
Lippman, SM .
NATURE REVIEWS CANCER, 2005, 5 (12) :930-942
[3]   HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway [J].
Fuchs, Dominik ;
Berges, Carsten ;
Opelz, Gerhard ;
Daniel, Volker ;
Naujokat, Cord .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (02) :309-314
[4]   Different proteins are phosphorylated under acidic environments in Jurkat cells [J].
Fukamachi, T ;
Saito, H ;
Kakegawa, T ;
Kobayashi, H .
IMMUNOLOGY LETTERS, 2002, 82 (1-2) :155-158
[5]  
Fukamachi T, 2006, ADV EXP MED BIOL, V584, P219
[6]   Differences in antitumor effects of various statins on human pancreatic cancer [J].
Gbelcova, Helena ;
Lenicek, Martin ;
Zelenka, Jaroslav ;
Knejzlik, Zdenek ;
Dvorakova, Gabriela ;
Zadinova, Marie ;
Pouckova, Pavla ;
Kudla, Michal ;
Balaz, Peter ;
Ruml, Tomas ;
Vitek, Libor .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (06) :1214-1221
[7]   Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) [J].
Gotto, AM ;
Whitney, E ;
Stein, EA ;
Shapiro, DR ;
Clearfield, M ;
Weis, S ;
Jou, JY ;
Langendörfer, A ;
Beere, A ;
Watson, DJ ;
Downs, JR ;
de Cani, JS .
CIRCULATION, 2000, 101 (05) :477-484
[8]   Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin [J].
Hawk, MA ;
Cesen, KT ;
Siglin, JC ;
Stoner, GD ;
Ruch, RJ .
CANCER LETTERS, 1996, 109 (1-2) :217-222
[9]   Interstitial pH and pO(2) gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation [J].
Helmlinger, G ;
Yuan, F ;
Dellian, M ;
Jain, RK .
NATURE MEDICINE, 1997, 3 (02) :177-182
[10]  
Herbst Roy S, 2003, Clin Adv Hematol Oncol, V1, P466